A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
Conditions
Neovascular Age-Related Macular Degeneration (NVAMD) · Branch Retinal Vein Occlusion (BRVO)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Scottsdale, Arizona, Scottsdale, Arizona, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Scottsdale, AZ, Scottsdale, Arizona, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Glendale, California, Glendale, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Glendale, CA, Glendale, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Modesto, California, Modesto, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Mountain View, California, Mountain View, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Sacramento, CA, Sacramento, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Sactamento, California, Sacramento, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Sacramento, California, Sacramento, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Santa Ana, California, Santa Ana, California, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Fort Lauderdale, Florida, Fort Lauderdale, Florida, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Fort Lauderdale, FL, Fort Lauderdale, Florida, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Lemont, Illinois, Lemont, Illinois, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Lemont, IL, Lemont, Illinois, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Hagerstown, Maryland, Hagerstown, Maryland, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Hagerstown, MD, Hagerstown, Maryland, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Madison, Mississippi, Madison, Mississippi, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Madison, MS, Madison, Mississippi, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Bloomfield, New Jersey, Bloomfield, New Jersey, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Bloomfield, NJ, Bloomfield, New Jersey, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Asheville, North Carolina, Asheville, North Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Cary, North Carolina, Cary, North Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Wake Forest, NC, Wake Forest, North Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Wake Forest, North Carolina, Wake Forest, North Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127West Columbia, SC, West Columbia, South Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127West Columbia, South Carolina, West Columbia, South Carolina, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Germantown, Tennessee, Germantown, Tennessee, United States
Knoxville, Tennessee, Knoxville, Tennessee, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Nashville, Tennessee, Nashville, Tennessee, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Nashville, TN, Nashville, Tennessee, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Abilene, Texas, Abilene, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Amarillo, Texas, Amarillo, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Austin, Texas, Austin, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Austin, TX, Austin, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Bellaire, Texas, Bellaire, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Bellaire, TX, Bellaire, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Burleson, Texas, Burleson, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Dallas, Texas, Dallas, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Dallas, TX, Dallas, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Plano, Texas, Plano, Texas, United States
Round Rock, TX, Round Rock, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Round Rock, Texas, Round Rock, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127San Antonio, Texas, San Antonio, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127San Antonio, TX, San Antonio, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127San Marcos, Texas, San Marcos, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127The Woodlands, Texas, The Woodlands, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127The Woodlands, TX, The Woodlands, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127Willow Park, Texas, Willow Park, Texas, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127West Jordan, Utah, West Jordan, Utah, United States
Contact: Study coordinator (Charles Miller, MD PhD) · ClinicalInquiries@eyebiotech.com · 212-914-0127
Study leads
Charles Miller, MD PhD
Study Director
EyeBiotech Ltd.